source
- Telix to acquire ITM Isotope Technologies in $1.65 billion radiopharma mergerITM Isotope Technologies Munich SE and Telix Pharmaceuticals announced a merger that will combine two leading radiopharmaceutical developers. The transaction is valued at a minimum of $1.65 billio…
- Beacon Therapeutics reports positive pivotal trial results for X-linked retinitis pigmentosa gene therapyBeacon Therapeutics said its gene therapy for X-linked retinitis pigmentosa (XLRP) met the primary endpoint in a phase 2/3 Vista study. The trial enrolled 85 male patients and compared two dose lev…